Metabolic Syndrome

Metabolic Diseases
9
Pipeline Programs
12
Companies
16
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
0
0
2
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 15 programs with unclassified modality

On Market (2)

Approved therapies currently available

U
BENICARApproved
olmesartan medoxomil
Unknown Company
oral2002
U
OLMESARTAN MEDOXOMILApproved
olmesartan medoxomil
Unknown Company
oral2023

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
2 programs
1
Fluvastatin XL®Phase 41 trial
Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome PatientsN/A1 trial
Active Trials
NCT00171548Completed600
NCT00664742Completed614Est. Oct 2007
Alliance Pharmaceuticals
1 program
1
PioglitazonePhase 41 trial
Active Trials
NCT00835120Completed34Est. Apr 2013
DS
Daiichi SankyoChina - Shanghai
2 programs
2
Olmesartan medoxomil tablets low dosePhase 31 trial
olmesartan medoxomilPhase 31 trial
Active Trials
NCT00891267Completed60Est. May 2011
NCT00676845Completed133Est. May 2011
Sagimet Biosciences
Sagimet BiosciencesCA - San Mateo
1 program
1
3-V Bioscience-2640Phase 1/21 trial
Active Trials
NCT02948569CompletedEst. Jan 2019
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
INV-202Phase 11 trial
Active Trials
NCT05282446Completed37Est. Oct 2022
Pfizer
PfizerNEW YORK, NY
1 program
1
RamiprilPhase 1Small Molecule1 trial
Active Trials
NCT00574834Terminated17Est. Aug 2014
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
3 programs
Metabolic Syndrome Observation on a Regional BasisN/A1 trial
Regional Observation of the Metabolic SyndromeN/A1 trial
Regional Observatory on Metabolic Syndrome- LAZION/A1 trial
Active Trials
NCT00933010Completed1,600Est. Oct 2010
NCT00874952Completed1,600Est. Feb 2010
NCT00689455Completed1,574Est. Dec 2008
Pulse Biosciences
Pulse BiosciencesCA - Hayward
1 program
CHANGE InterventionN/A1 trial
Active Trials
NCT02893163CompletedEst. Jan 2023
Amgen
AmgenTHOUSAND OAKS, CA
1 program
EtanerceptN/A1 trial
Active Trials
NCT00409318Completed56Est. May 2005
M&
Merck & Co.RAHWAY, NJ
1 program
GLP-1 infusionN/A1 trial
Active Trials
NCT00856700Completed20Est. Jun 2012
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Pharmacogenetic Profiling of Antipsychotics-Induced X-Syndrome and Diabetes (PAXD)N/A1 trial
Active Trials
NCT00201292UnknownEst. Oct 2008
Design Therapeutics
1 program
Standard health coachingN/A1 trial
Active Trials
NCT04262401UnknownEst. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alliance PharmaceuticalsPioglitazone
NovartisFluvastatin XL®
Daiichi SankyoOlmesartan medoxomil tablets low dose
Daiichi Sankyoolmesartan medoxomil
Sagimet Biosciences3-V Bioscience-2640
Novo NordiskINV-202
PfizerRamipril
Design TherapeuticsStandard health coaching
Pulse BiosciencesCHANGE Intervention
AstraZenecaMetabolic Syndrome Observation on a Regional Basis
AstraZenecaRegional Observation of the Metabolic Syndrome
Merck & Co.GLP-1 infusion
AstraZenecaRegional Observatory on Metabolic Syndrome- LAZIO
City TherapeuticsPharmacogenetic Profiling of Antipsychotics-Induced X-Syndrome and Diabetes (PAXD)
NovartisCardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients

Showing 15 of 16 trials with date data

Clinical Trials (16)

Total enrollment: 6,345 patients across 16 trials

NCT00835120Alliance PharmaceuticalsPioglitazone

Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance

Start: Mar 2009Est. completion: Apr 201334 patients
Phase 4Completed
NCT00664742NovartisFluvastatin XL®

The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome

Start: Sep 2006Est. completion: Oct 2007614 patients
Phase 4Completed
NCT00891267Daiichi SankyoOlmesartan medoxomil tablets low dose

Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome

Start: Oct 2008Est. completion: May 201160 patients
Phase 3Completed
NCT00676845Daiichi Sankyoolmesartan medoxomil

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection

Start: Aug 2008Est. completion: May 2011133 patients
Phase 3Completed
NCT02948569Sagimet Biosciences3-V Bioscience-2640

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Start: Feb 2017Est. completion: Jan 2019
Phase 1/2Completed
NCT05282446Novo NordiskINV-202

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome

Start: Mar 2022Est. completion: Oct 202237 patients
Phase 1Completed
NCT00574834PfizerRamipril

Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes

Start: Mar 2007Est. completion: Aug 201417 patients
Phase 1Terminated
NCT04262401Design TherapeuticsStandard health coaching

Promoting Healthy Habits in Metabolic Syndrome

Start: Nov 2020Est. completion: Dec 2024
N/AUnknown
NCT02893163Pulse BiosciencesCHANGE Intervention

CHANGE Cancer Alberta: A Primary Care Program for Cancer Prevention and Screening

Start: Aug 2016Est. completion: Jan 2023
N/ACompleted
NCT00933010AstraZenecaMetabolic Syndrome Observation on a Regional Basis

Metabolic Syndrome Observation on a Regional Basis

Start: Oct 2009Est. completion: Oct 20101,600 patients
N/ACompleted
NCT00874952AstraZenecaRegional Observation of the Metabolic Syndrome

Regional Observation of the Metabolic Syndrome

Start: Mar 2009Est. completion: Feb 20101,600 patients
N/ACompleted
NCT00856700Merck & Co.GLP-1 infusion

Glucagon-like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome

Start: Nov 2008Est. completion: Jun 201220 patients
N/ACompleted
NCT00689455AstraZenecaRegional Observatory on Metabolic Syndrome- LAZIO

Regional Observatory on Metabolic Syndrome- LAZIO

Start: Oct 2007Est. completion: Dec 20081,574 patients
N/ACompleted
NCT00201292City TherapeuticsPharmacogenetic Profiling of Antipsychotics-Induced X-Syndrome and Diabetes (PAXD)

Pharmacogenetic Profiling of Antipsychotics-Induced X-Syndrome and Diabetes (PAXD)

Start: Mar 2005Est. completion: Oct 2008
N/AUnknown
NCT00171548NovartisCardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients

Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients

Start: Oct 2004600 patients
N/ACompleted
NCT00409318AmgenEtanercept

Study of TNF-Antagonism in Metabolic Syndrome

Start: Apr 2004Est. completion: May 200556 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
20h ago

(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)

Johnson & Johnson
Beerse, Antwerp, Belgium
Yesterday

Computational Chemist

Topos Bio
San Francisco Office
2d ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr

Senior Specialist, Quality Management Systems

Crinetics Pharmaceuticals
San Diego, CA
4d ago
$91K - $114K/yr

Director, Quality Systems, Project Management, QRM, RS

Crinetics Pharmaceuticals
US California
4d ago
$178K - $223K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
12 companies competing in this space

Related Indications

Diabetes(737)Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes(207)Type 2 Diabetes Mellitus(190)Diabetes Mellitus(127)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)